Detact Diagnostics
Detact Diagnostics is a Netherlands-based diagnostics company developing the VIPER® NIR fluorescence platform and DeNIRO® mini reader for rapid point-of-care detection of viable bacterial, fungal, and viral pathogens, serving healthcare providers, LMICs, and dairy industry customers.
- Company typePrivate
- Founded2014
- HeadquartersDelfzijl, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Detact Diagnostics does
Detact Diagnostics B.V. is a Netherlands-based private diagnostics company founded in 2014 that has developed the proprietary VIPER® platform — a near-infrared (NIR) fluorescence detection system capable of identifying viable bacterial, fungal, and viral pathogens in real time without culture-based delays. The platform underpins a portfolio of point-of-care products: the DeNIRO® mini portable NIR fluorometer reader and five indication-specific assay kits — RenoTact® (peritoneal dialysis peritonitis), SynoTact® (periprosthetic joint infections), MycoTact® (tuberculosis), SpiroTact® (syphilis), and EnzoTact® (dairy protease detection for milk spoilage).
The company monetizes through sale of assay kits and the DeNIRO® mini hardware to healthcare providers, dialysis and orthopedic clinics, global health programs, and dairy producers, targeting both high-resource and LMIC markets with low-cost, easy-to-use diagnostics. To date, Detact has funded operations primarily through six Bill & Melinda Gates Foundation grants (totaling roughly $7.5M) plus earlier NV NOM support, and remains pre-commercial with products in pilot or pre-clinical stages. The firm is ISO 13485 certified, holds 50+ patent rights, and operates from offices and a laboratory in Groningen with a core leadership team of approximately nine people spanning R&D, operations, QA/RA, and device engineering.
Detact Diagnostics firmographics
Firmographics- Name
- Detact Diagnostics
- Legal name
- Detact Diagnostics B.V.
- Website
- https://detactdiagnostics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Detact Diagnostics is a Netherlands-based diagnostics company developing the VIPER® NIR fluorescence platform and DeNIRO® mini reader for rapid point-of-care detection of viable bacterial, fungal, and viral pathogens, serving healthcare providers, LMICs, and dairy industry customers.
- Ownership category
- akta.pro rank
Detact Diagnostics industry classification
Industry- Product category
- Point-of-Care Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
- akta.pro secondary industry
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
Keywords
Where Detact Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Delfzijl
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Detact Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Test Kits and Assays: Sale of VIPER®-based assay products including RenoTact®, SynoTact®, MycoTact®, SpiroTact®, and EnzoTact® for specific infection detection applications.
- DeNIRO® mini Hardware: Sale of the DeNIRO® mini portable NIR fluorometer device, a handheld point-of-care reader compatible with VIPER® assay tests.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Detact Diagnostics product offering
Product offeringCore offering
Detact Diagnostics develops and sells rapid infection diagnostic products built on its proprietary VIPER® platform, a near-infrared (NIR) fluorescence-based detection system that directly identifies viable bacterial, viral, and fungal pathogens in real time. Its commercial portfolio includes the DeNIRO® mini portable NIR fluorometer reader and a series of assay kits (RenoTact®, SynoTact®, MycoTact®, SpiroTact®, EnzoTact®) targeting peritoneal dialysis peritonitis, prosthetic joint infections, tuberculosis, syphilis, and dairy protease contamination.
Product overview
Detact Diagnostics offers a platform-plus-products architecture centered on the proprietary VIPER® technology platform. VIPER® provides rapid, NIR fluorescence-based detection of viable pathogens for infection diagnostics. The product portfolio includes the DeNIRO® mini portable fluorometer hardware device, plus six VIPER®-based diagnostic tests: RenoTact® for peritoneal dialysis peritonitis, SynoTact® for periprosthetic joint infections, MycoTact® for tuberculosis, SpiroTact® for syphilis, and EnzoTact® for milk protease detection (food safety). VIPER® assays integrate with the DeNIRO® mini for point-of-care use or with lab-based plate readers for high-throughput settings.
Differentiator
Problem solved
Functional benefit
Brands
- RenoTact®: Rapid detection test for peritoneal dialysis-related peritonitis
- SynoTact®
- MycoTact®
- SpiroTact®
- EnzoTact®
- DeNIRO® mini
- VIPER®
Products and services
- VIPER® Platform Technology Proprietary near-infrared (NIR) fluorescence-based detection platform that directly identifies viable pathogens in real time, eliminating the need for lengthy culture-based diagnostics and enabling actionable results within minutes for healthcare providers and industrial laboratories.
- DeNIRO® mini Compact, battery-operated, handheld NIR fluorometer that pairs with VIPER® assays to deliver real-time infection detection by quantifying emitted fluorescence triggered by target pathogens; provides point-of-care results within seconds for clinicians in hospitals, clinics, and field settings.
- RenoTact® Rapid diagnostic test for early detection of peritoneal dialysis-related peritonitis that detects infection-related protease activity within minutes from a small PD waste fluid sample, targeting dialysis centers monitoring PD patients for peritonitis.
- SynoTact® Rapid diagnostic test for periprosthetic joint infections (PJIs) that directly identifies causative bacterial agents in synovial fluid, enabling fast treatment decisions for orthopedic surgeons differentiating postoperative inflammation from infection.
- MycoTact® Rapid, user-friendly test for direct detection of viable Mycobacterium tuberculosis within minutes, designed for healthcare providers addressing global tuberculosis diagnostics in high-burden regions.
- SpiroTact® Rapid, user-friendly diagnostic test for direct detection of active Treponema pallidum (syphilis), designed to differentiate from past infections unlike traditional serological tests; intended for STI clinics and primary healthcare facilities in LMICs.
- EnzoTact® Rapid protease detection test for the dairy industry that prevents milk spoilage by detecting protease-producing bacteria in raw and post-pasteurized milk within 45-60 minutes, addressing quality assurance needs of dairy producers.
Quantifiable outcome
- Actionable data delivered within minutes (45-60 minutes for EnzoTact® protease detection)
- +3 more outcomes
Companies that use Detact Diagnostics
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles5 records
Detact Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Detact Diagnostics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Foundation for Professional Development (FPD)majorCollaboration with FPD in East London, South Africa for SpiroTact® syphilis diagnostic development. Team members conducted site visits at STI clinics and primary healthcare facilities to understand frontline healthcare worker needs and gather feedback to shape product development for real-world settings in communities most affected by syphilis.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Detact Diagnostics competitors and assessment
Company assessmentEmerging players
- Trinity Biotech: Specialty diagnostics developer with rapid infectious disease tests including syphilis (Trinity Mercia). Comparable niche scale to Detact and overlapping syphilis diagnostics target, though Trinity's portfolio is broader and includes HbA1c and autoimmune assays.
- T2 Biosystems: US-based developer of rapid molecular diagnostics (T2 Magnetic Resonance platform) for sepsis and other bloodstream infections. Comparable to Detact in seeking faster, non-culture-based bacterial detection but with a different (T2MR) technology and broader bloodstream-infection focus.
- OpGen (Curetis): Molecular diagnostics company focused on rapid identification of bacterial pathogens and antimicrobial resistance, including Unyvero platform for bloodstream and synovial fluid infections. Directly comparable to Detact's SynoTact PJI detection application and shares the early-stage commercial profile.
Broad incumbents
- bioMérieux: Global leader in microbiology diagnostics (culture, ID/AST, molecular) serving hospital labs with established regulatory clearances and installed instrumentation. Comparable to Detact in targeting microbiology and infectious disease workflow but operates as a broad incumbent rather than POCT niche specialist.
- Abbott Rapid Diagnostics: Owner of BinaxNOW, Alinity, and m-PIMA HIV POCT platforms, all targeting rapid infectious disease testing including in LMIC settings. Directly comparable to Detact's TB and syphilis ambitions with established global distribution and WHO prequalification on several products.
- Becton, Dickinson and Company (BD): Major diagnostics and life sciences company with BD MAX molecular POCT system and extensive microbiology portfolio. Overlaps with Detact's TB, syphilis, and bacterial infection detection targets, but operates at much broader scale across multiple diagnostic segments.
- QuidelOrtho: Specialty diagnostics company with Sofia rapid antigen POCT platform and Triage infectious disease products. Comparable to Detact in delivering fast, easy-to-use infectious disease diagnostics, though QuidelOrtho's portfolio spans far more indications and geographies.
- Roche Diagnostics: Global diagnostics leader with cobas Liat POCT molecular system cleared for Strep A, influenza, RSV, and other infectious diseases. Comparable to Detact's POCT infectious disease positioning but as part of a vast menu across central lab and near-patient testing.
Direct peers
- Cepheid (a Danaher company): Market-leading molecular POCT platform (GeneXpert) with cleared TB, syphilis, and other infectious disease assays on a bench-top cartridge system. Directly comparable to Detact's VIPER®/DeNIRO® mini approach targeting the same LMIC and hospital customers with rapid, single-pathogen tests.
- Mologic: UK-based rapid diagnostic developer focused on affordable POCT for infectious disease in LMICs, including TB and syphilis. Highly comparable mission and target customer base to Detact, with overlapping Gates Foundation funding profile and lateral flow / rapid test technology approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Detact Diagnostics social profiles
Digital presenceDetact Diagnostics compliance and trust
Trust signalCompliance1 record
Detact Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Detact Diagnostics leadership team
Management profileNumber of profiles
Profiles10 records
Detact Diagnostics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Detact Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Detact Diagnostics
What does Detact Diagnostics do?
Detact Diagnostics develops and sells rapid infection diagnostic products built on its proprietary VIPER® platform, a near-infrared (NIR) fluorescence-based detection system that directly identifies viable bacterial, viral, and fungal pathogens in real time. Its commercial portfolio includes the DeNIRO® mini portable NIR fluorometer reader and a series of assay kits (RenoTact®, SynoTact®, MycoTact®, SpiroTact®, EnzoTact®) targeting peritoneal dialysis peritonitis, prosthetic joint infections, tuberculosis, syphilis, and dairy protease contamination.
Is Detact Diagnostics a public or private company?
Detact Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Detact Diagnostics founded?
Detact Diagnostics was founded in 2014. It employs 1 to 10 people.
Where is Detact Diagnostics based?
Detact Diagnostics is headquartered in Delfzijl, Netherlands, in the Europe region.
How does Detact Diagnostics make money?
Two revenue lines are on record. Diagnostic Test Kits and Assays are the primary driver. The others are deNIRO® mini Hardware.
Who are Detact Diagnostics's main competitors?
Emerging players on record are Trinity Biotech, T2 Biosystems and OpGen (Curetis). Broad incumbents are bioMérieux, Abbott Rapid Diagnostics, Becton, Dickinson and Company (BD), QuidelOrtho and Roche Diagnostics. Direct peers are Cepheid (a Danaher company) and Mologic.
Does Detact Diagnostics have an API?
No public API is recorded for Detact Diagnostics.
What industry is Detact Diagnostics in?
Detact Diagnostics's product category is Point-of-Care Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.